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Background: The present study is designed to assess the incidence rate of osteoporotic fracture and its risk factors,
particularly those used to predict the 10-year risk of osteoporotic fracture in FRAX based on the data gathered
through a follow up cohort initiated in 2000.
Methods: The present retrospective cohort was conducted on men and women from 40 to 90 years of age
enrolled in the IROSTEOPs study. A phone survey was conducted during 2013 and beginning of 2014 to assess the
fractures (traumatic/osteoporotic) occurring at the time of inclusion until the date of the telephone survey, its type
and mechanism, and the patient’s age at the time of accident. Survival analysis using Kaplan-Meier product-limit
method was performed with the time of fracture as the study outcome.
Results: Final study population consisted of 1233 individuals, translated in to 9133 person years. The incidence rate
of osteoporotic fracture was reported to be 359.1 cases in every 10,000 person years. The 10-year Kaplan-Meier
estimate of any kind of major osteoporotic fractures for all the subcohort population was 10.75%. Osteoporosis
(HR = 0.75), Discordance between femoral neck and spine (HR = 1.45), Diabetes (HR = 1.81), IBD (HR = 1.84), immobility
more than 90 days (HR = 2.19), and personal history of fracture (HR = 7.75) had a considerable effect on the 10-year risk
of major osteoporotic fractures.
Conclusions: Adding new clinical risk factors to FRAX® may help improve fracture prediction in the Iranian population.
Keywords: Fracture, FRAX, Major osteoporotic fractureIntroduction
Osteoporosis is becoming a health concern worldwide,
with statistics showing that 200 million adults suffer from
the condition [1]. In Iran, 22.2% and 59.9% of women aged
over 50 and 11.0% and 50.1% of men of the same age group
are diagnosed with osteopenia and osteoporosis, respect-
ively [2]. Recent projections indicate that by 2050, approxi-
mately, 44 million will be suffering from some degree of
osteopenia and 5 million will be affected by osteoporosis.
Osteoporotic fracture is usually the first manifestation
and the main complication of the condition, imposing a* Correspondence: pkhashayar@farabi.tums.ac.ir
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unless otherwise stated.heavy burden on the family and society. According to
available statistics, 620,000 new hip fractures, 575,000
shoulder fractures, 250,000 proximal humorous fractures
and 620,000 symptomatic vertebral fractures were re-
ported in subjects over the age of 50 years in Europe in
2000, representing almost 35% of the fractures reported
in the world [3]. The direct costs of osteoporotic frac-
ture in Europe are estimated to be around 36 billion
Euros per year [4].
In a study designed to assess falls leading to hip frac-
ture, Abolhassani et al. found that the crude annual inci-
dence of falls and related hip fractures in Iran for those
aged over 50 was 237.1 and 93.6 per 100,000 person
years, respectively [5]. Based on these results, the num-
ber of hip fractures in people aged over 50 years wasl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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2010. In a nationwide prospective study designed to as-
sess the burden of hip fracture in Iran, the country
accounted for 0.85% of the global burden of hip fracture
and 12.4% of the burden of hip fracture in the Middle
East [6].
As demonstrated elsewhere, fracture history is one of
the strongest risk factors for subsequent fractures [7].
Therefore, it is imperative to identify patients at risk of
fracture to implement preventive measures and identify
those who would benefit from pharmacological interven-
tion. In response to this demand, recently, a number of
prognostic models have been developed which basically
rely on the results of bone density measurements as well
as some other recognized risk factors for osteoporotic
clinical risk fracture (CRFs) [8].
The most widely used osteoporotic fracture risk meas-
urement tool, FRAX®, was invented in 2008 by a WHO
Collaborating Center for Metabolic Bone Diseases at
Sheffield. The FRAX® tool is developed to compute age-
specific fracture probabilities based on CRFs for fracture,
identified from large population-based cohorts with over
a million person-years of observation, and bone mineral
density (BMD) measurements at the femoral neck [9].
The FRAX® tool calculates the 10- year probability of
major (clinical spine, hip, forearm or proximal hum-
mers) and hip osteoporotic fracture adjusted to the frac-
ture and death hazards of several countries.
Since its introduction, FRAX® has been calibrated for
several nations [10]. In order for FRAX® to be calibrated
and used in a particular nation, it is important to design
cohort studies by means of which FRAX® parameters
can be objectively assessed. Unfortunately the tool is not
yet validated for the Iranian population as there has
been no population-based cohorts for the development
of the FRAX® algorithm in the country.
The extension of the tool for calculating the probabil-
ity of fractures using the FRAX® is foreseeable in Iran
similar to what is occurring in other countries and this
would justify a study to allow the necessary adjustments
in calibration of the parameters included in the logarith-
mic formula constituted by FRAX®.
It is therefore reasonable to validate the tool in a co-
hort on patients who visit different healthcare levels for
diagnosis, treatment and follow up of osteoporosis be-
fore the generalized use of the tool in medical centers
around the country.
Moreover, recent evidence also recommend the evalu-
ation of other risk factors related to low bone mass and
higher risk of fragility fracture that are not considered in
the FRAX® tool when assessing fracture risk [11,12].
The present study was therefore conducted to assess
the incidence rate of osteoporotic fracture and its risk
factors and compare them with those used to predict the10-year risk of osteoporotic fracture in FRAX® based on
the data gathered through a follow up cohort initiated in
2000.
Material and methods
The present retrospective cohort was conducted on men
and women from 40 to 90 years of age enrolled in the
IROSTEOPs study. The IROSTEOPS (Iranian Osteoporosis
Study) is the largest prospective cohort conducted in Iran
to predict the prevalence of osteoporosis based on BMD
measurement parameters and the recognized risk factors of
osteoporosis and related fractures, including those used in
the FRAX® tool. This cohort included men and women re-
ferred to the BMD clinic of Shariati Teaching Hospital for
central bone densitometry by Dual-energy X-ray absorpti-
ometry (DXA) as the initial evaluation of osteoporosis or
treatment follow up. During the past decade, more than
13,000 individuals with the median of 1,000 patients per
year were visited at this clinic. The referral criteria followed
the existing recommendations and was not for screening
[13,14]. However considering the fact that our hospital is a
referral hospital, it could be concluded that our results is
higher than other BMD clinics but more likely to be an es-
timation of the whole country.
Since the establishment of our BMD clinic, an extensive
questionnaire on individuals’ demographic and socioeco-
nomic data, bone-health-related lifestyle habits, medical
and drug history, and a semi-quantitative Food Frequency
Questionnaires (FFQ) was filled out for every individual.
The studied CRFs utilized were those identified from pre-
vious meta-analyses. The collected data was stored in a
specific database for further studies such as this cohort.
Bone Mineral Density measurements at lumbar spine
and hip were determined using dual-energy X-ray absorp-
tiometry (Lunar DPXM, Lunar, 1999) following conven-
tional procedures.
In order to assess the incidence of osteoporotic fracture,
a phone survey was conducted during 2013 and beginning
of 2014 on those who accepted to answer the follow-up
questions. The follow-up study was approved by the
Ethical Board Committee of the Endocrinology and Me-
tabolism Research Institute affiliated with Tehran Univer-
sity of Medical Sciences. The telephone questionnaire
collected data regarding fractures (traumatic/osteoporotic)
occurring at the time of inclusion until the date of the
telephone survey, its type and mechanism, and the pa-
tient’s age at the time of accident.
Fragility or osteoporotic fractures were defined as
those which occur from a fall from a standing height or
less, or presenting in the absence of obvious trauma.
These fractures were categorized in two main groups:
hip fractures or major osteoporotic fractures [15].
Subjects aged less than 40 or over 90 years of age at
the time of the first visit to our clinic were excluded
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risk outside this age range. Individuals not providing con-
sent to answer the questions as well as those without a
telephone to contact, who had moved or their phone
number had changed or did not respond after three calls
made at different times according to the protocol were
excluded.
For the main objective (calculating the incidence rate of
osteoporotic fracture rate in a prospective cohort using sur-
vival analysis), a sample of 1,000 individuals was needed
based on the study conducted by Kanis et al [16].
To minimize the effect of possible losses, which may
imply bias (given the mortality associated with fractures
and possible address change over 10 years), the sample
size was increased to 2,000. This increase also aims to
minimize the losses to follow up or refusal to participate.
This subgroup constituted 15% of the whole number of
patients who had visited our BMD center between 2000
and 2010. In order to minimize the difference between the
prevalence of various risk factors in this group compared
to the whole population, the subsample was selected
through stratified sampling (Each year was considered as a
stratification) and the number of samples in each stratifi-
cation was proportional to size (Table 1).
Descriptive statistics for demographic and baseline char-
acteristics were presented as mean and standard deviation
for continuous variables or count (percent) for categorical
variables. Simple comparisons of the baseline charac-
teristics were made among the participants and non-
participants of the cohort. The Chi-square test was used
to evaluate the association between qualitative variables.
The Student’s t-test was implemented to evaluate the dif-
ferences in the distribution of quantitative variables ac-
cording to the categories defined by a binary exposure.
To assess the differences in the distribution of quantita-
tive variables with more than 2 categories, ANOVATable 1 The distribution of the subsample to the whole





Total no. of visitors
to the BMD clinic
Cohort subsample/
total visitors ratio
2000 381 2506 15.2
2001 217 1595 13.6
2002 382 2785 13.7
2003 216 1303 16.6
2004 97 872 11.1
2005 164 1244 13.2
2006 132 862 15.3
2007 146 880 16.6
2008 164 764 21.5
2009 161 802 20.1
Total 2060 13613 15.1analysis of variance or its corresponding non-parametric
test (Kruskal-Wallis) were used. Individuals were grouped
into risk quintiles based on the hip and osteoporotic
FRAX estimates using BMD, with men and women cat-
egorized separately. According to the literature, individ-
uals are classified in four main groups in osteoporosis
studies: Men aged less than 50 yrs, Men aged over
50 yrs, Premenopausal Women, and Postmenopausal
Women. In view of the fact that women compromised
more than 90% of the studied population, all the men
were classified in a single group.
The time of the fracture was considered as the study
outcome and survival analysis was conducted. The survival
curves, for all the study participants and different predic-
tors, were estimated using the Kaplan-Meier product-limit
method. The log rank test was used to compare the sur-
vival curves between the exposure groups. Univariable and
multivariable cox proportional hazard regression were
used to determine the hazard ratio of fracture based on
risk facture.
The cox model assumption (proportional hazard as-
sumption) was assessed using log-minus-log plot. The cox
regression was performed as following: First, potential risk
factors, including all indicated in FRAX®, were imple-
mented in the univariable cox regression analysis. Then
variables significantly associated with fracture, with p-
value lower than 0.20, were retained for the multivariate
analysis. The beta coefficient of cox regression indicated
hazard ratio with 95% confidence intervals (CIs). Parallel
analyses were performed for osteoporotic fractures and
hip fractures. All the statistical tests were set two-sided.
Significant p-values for multivariable method were set
lower than 0.05. Statistical analyses were performed with
Stata (Version 11, USA) and SPSS for Windows (Version
16.0, SPSS, Inc., Chicago, IL, USA).
Results
The final study population consisted of 1233 individuals,
translated in to 9133 person years. Mean age at the time
of first visit was 54.2 ± 11.5 years in the cohort subsample.
The cooperation rate was about 59.9%. One hundred sixty
individuals (7.8%) could not be contacted due to address
change and 16 (0.7%) had died during the follow-up
period.
Osteoporosis at any site was reported in 19.9% of the
studied men and 34.8% of the studied women (P-value <
0.001). During the mean follow-up period of 7.41 ±
3.27 years ranging from 5 to 13 years, participants sus-
tained 328 fractures (osteoporotic/traumatic), suggesting
an incidence rate of about 359.1 cases in every 10,000 per-
son years. From among them, 23 cases were osteoporotic
hip fractures (incidence rate = 25.2 in every 10,000 person
years) and 165 were major osteoporotic fractures (inci-
dence rate = 61.3 in every 10,000 person years) (Table 2).
Table 2 The prevalence of CRFs mentioned in FRAX® in different age-sex groups
Variables Age-sex groups Total (n = 2060) P-value




Corticosteroid use 24/88 (27.3) 50/212 (33.6) 55/511 (10.8) 129/811 (15.9) <0.001
Type II diabetes 17 (10.2) 25 (6.1) 165 (12.5) 207 (10.1) <0.001
Parental fracture history 4 (2.4) 25 (6.1) 54 (4.0) 93 (4.5) 0.06
Personal fracture history 10 (6.0) 18 (3.1) 52 (3.9) 80 (3.9) 0.23
History of major osteoporotic fracture 9 (5.4) 11 (1.9) 31 (2.4) 51 (2.5) 0.03
History of rheumatoid arthritis 3 (1.8) 8 (1.4) 5 (0.4) 16 (0.8) 0.02
History of hyperthyroidism 8 (4.8) 32 (5.6) 72 (5.5) 112 (5.4) 0.93
Early menopause (before 45) - - 363 (27.5) 363 (17.6)
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osteoporotic fractures for all the subcohort population
was 10.75% (p-value = 0.0046) (Figure 1). For women, the
10-year major osteoporotic fracture risk was 10.45%
(p-value = 0.0055).
There was a significant difference between sun expos-
ure among these groups. Based on the results, 76.7%,
78.3%, and 61.4% of postmenopausal women, premeno-
pausal women, and men had no daily sun exposure, re-
spectively. Smoking (p-value = 0.01), and alcohol abuse
(p-value = 0.23) were more frequent among men. There
was however no significant difference in long-term im-
mobility and walking behavior of the age-sex groups.
The prevalence of corticosteroid use (p-value < 0.001),
type II diabetes (p-value < 0.001), rheumatoid arthritis
(p-value = 0.02), history of major osteoporotic fracture
(p-value = 0.03) were different among the studied groups.















Figure 1 10-year Kaplan-Meier estimate of major osteoporotic fracturand without osteoporotic fracture, was the only signifi-
cantly different variable (Table 3).
The resulting osteoporotic fracture incidence rates based
on the studied CRFs are listed in Table 4. It could be seen
that fracture sufferers were mainly postmenopausal women
with a history of early menopause, immobility for more
than 90 days, osteoporosis at any site, discordance between
spine and femoral neck, rheumatoid arthritis, type II dia-
betes, hyperthyroidism and IBD. They were more likely to
use corticosteroid and to be smoker or use alcohol. We
conducted a separate analysis on those who had osteopor-
otic hip fracture and ended up with the same group of
predictors.
According to the results of the Multivariate logistic
regression analysis, each clinical risk factor had different
significance for osteoporotic fracture probability with
osteoporosis (HR = 0.75), Discordance between femoral




es for the subcohort population.
Table 3 The demographic variables in individuals with and without a previous history of osteoporotic fracture
Variables Without fracture (n = 905) With fracture (n = 328) Total (n = 1233) P-value
Gender Male 52 (5.8) 25 (7.6) 77 (6.2) 0.23
Female 853 (94.2) 303 (92.4) 1156 (93.8)
Menopause Early 143 (15.8) 59 (18.0) 202 (16.4) 0.46
Normal 444 (49.1) 151 (46.0) 595 (48.3)
Age at inclusion (Mean ± SD) 54.1 ± 14.5 54.3 ± 11.6 54.2 ± 11.5 0.88
Age at follow-up (Mean ± SD) 62.3 ± 11.8 62.4 ± 12.2 62.3 ± 11.9 0.86
Body Mass Index (BMI) 27.5 ± 0.16 27.5 ± 0.26 27.5 ± 0.14 0.95
Osteoporosis at any site 191/859 (22.2) 84/314 (26.8) 275/1173 (23.4) 0.09
Discordance between lumbar and femoral neck Major 15/859 (1.8) 16/314 (5.1) 31/1173 (2.6) 0.001
Minor 257/859 (29.9) 111/314 (35.4) 368/1173 (31.4)
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and personal history of fracture (HR = 7.75) having a con-
siderable effect. The hazard ratios and corresponding 95%
CIs associated with each of these variables are presented
in Table 5. Hazard ratio estimates with osteoporotic frac-
ture in the whole population were of approximately the
same magnitude than those in the female subgroup. This
is while age higher than 65 was also associated with 2.62%
higher risk of fracture in the whole sub-cohort population.Discussion
Several studies showed that the presence of the risk factors
used to trigger a BMD test is associated with a fracture
risk greater than that can be accounted for by BMD alone
[17,18]. Thus, the assessment of fracture risk should take
account of specific risk factors that contribute to fracture
risk in addition to BMD, since this would increase the sen-
sitivity of fracture prediction.
WHO fracture risk assessment tool is a scale including
11 of the CRFs (age, body mass index (BMI), prior fragility
fracture, parental history of hip fracture, current tobacco
smoking, long-term use of oral glucocorticoids, rheuma-
toid arthritis, other causes of secondary osteoporosis, daily
alcohol consumption), which have demonstrated a strong
association with the incidence of fracture in literature [19].
Factor number 12 in this scale also includes a single value
of DXA: the T-score of the femoral neck.
The relationships between risk factors and fracture
risk incorporated within FRAX® have been constructed
based on information derived from nine population-
based cohorts from around the world and has been vali-
dated in 11 independent cohorts (mainly women) with a
similar geographic distribution with in excess of 1 mil-
lion patient years [20]. The large sample used for the
model construction permits the determination of the
predictive importance in a multivariable context of each
of the risk factors, as well as interactions between riskfactors, and thereby optimizing the accuracy by which
fracture probability can be computed.
However, it is demonstrated that fracture risk assess-
ment cannot entirely replace objective examinations, as
the 10-year probability of fracture varies markedly in dif-
ferent countries [21,22]. Moreover, several studies have
reported that the number of cases of fracture estimated
or expected by FRAX® are significantly lower than the
incidental fractures actually observed in the 10 years of
follow up [23]. According to the French OFELY cohort,
the predicted major osteoporotic fracture probability
among women aged 65 years and older was 48% lower
than the actual observed fracture incidence [24]. More-
over, a recent study from New Zealand in older postmeno-
pausal women also showed that FRAX® underestimated
osteoporotic fractures [25]. However, in a preliminary re-
port from the Framingham Osteoporosis Study, FRAX®
yielded excellent results in predicting the probability of
hip fractures [26]. This inconsistency may be due to differ-
ences not only in risk factor distribution but also in the
definition of osteoporotic fracture.
Furthermore, others have pointed out the importance of
other risk factors such as vitamin D deficiency, falls, phys-
ical activity, bone turnover markers, previous treatment
for osteoporosis, and certain medications for decision-
making in the management of osteoporosis in primary
healthcare settings [27]. The measurement of a risk factor
for diagnostic use, however, can only capture one aspect
of the likelihood of the outcome when the disease is multi-
factorial such as osteoporosis.
Although it can be argued that the smaller proportion
of men in the studied populations could have posed
some limitations to the results, there was reasonable
agreement between estimated 10-year Kaplan-Meier es-
timate of osteoporotic fractures between women and the
whole subcohort population.
The prevalence of fracture obtained in the current
study was 359.1 in every 10,000 person year (equal to
Table 4 Incidence rate of osteoporotic fractures based on the studied CRFs
Risk factor Classification Osteoporotic fracture (N) At-risk patient years Incidence rate*
Age-sex groups Men 9 469 191.9
Premenopausal women 38 2819 134.8
Postmenopausal women 117 5845 200.2
Menopause age After 45 84 4479 151.4
Before 45 33 1366 241.6
Immobility None 66 3584 184.2
Less than 90 days 40 1792 223.2
More than 90 days 20 396 505.1
Osteoporosis femoral neck Normal 79 5106 154.7
Osteopenia 59 2907 203.0
Osteoporosis 19 885 214.7
Discordance between lumbar and femoral neck None 81 5923 136.8
Minor 66 2719 242.7
Major 10 228 438.6
Rheumatoid arthritis No 155 8689 178.4
Yes 9 444 202.7
BMI Normal 51 2735 186.5
Overweight 70 3951 177.2
Obese 39 2336 167.0
Type II diabetes No 139 8372 166.0
Yes 25 761 328.5
Daily sun exposure > 30 min 1 152 65.8
< 30 min 31 1361 227.8
None 132 7620 173.2
Hyperthyroidism No 149 8410 177.2
Yes 15 723 207.5
Corticosteroid use No 110 6597 166.7
Yes 54 2536 212.9
IBD No 134 6867 195.1
Yes 21 661 317.7
Smoking No 157 8915 176.1
Yes 7 218 321.1
Alcohol abuse No 160 8965 178.5
Yes 4 161 248.5
*in 10,000 individual.
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pausal and 200.2 in postmenopausal women) is higher
than the prevalence reported elsewhere in the literature
[28]. The ECOSAP cohort showed the incidence of hip
and major osteoporotic fracture in the Spanish popula-
tion to be about 0.96% and 3.81% [29]. In one study on
the Canadian population, Leslie et al. reported the inci-
dence of osteoporotic fracture to be about 10.7% in men
and 12% in women [30]. Maharlouei et al. reported the
incidence rate of hip fracture in men and women fromShiraz was 329 and 580 cases in every 100,000 popula-
tion [31]. Valizadeh et al. similarly reported the inci-
dence of hip fracture in Zanjan to be 206.5 and 214.8
per 100,000 men and women, respectively [32].
Another problem concerns the threshold for manage-
ment application. In other words, the scale should be de-
veloped and validated in each country, taking into account
the differences in fracture and risk factor epidemiological
data, their mortality data as well as cost-effectiveness stud-
ies to obtain an approximation of the cost, which each
Table 5 Hazard ratios and corresponding 95% CIs associated with each of the studied CRFs in uni and multivariate
analysis
Variables Classification Univariate Multivariate
Crude hazard ratio
(CI95 %)
P-value Crude hazard ratio
(CI95 %)
P-value
Age-group <50 yrs Reference Reference
50-64 yrs 1.07 0.72 0.86 (0.50-1.48) 0.59
≥ 65 yrs 1.88 0.006 1.77 (0.73-2.58) 0.33
Menopause age - Reference Reference
Before 45 1.88 0.008 1.40 (0.77-2.54) 0.27
After 45 1.43 0.067 1.00 (0.55-1.79) 0.99
T-score at femoral neck Each SD decrease in T-score 0.68 <0.001 0.75 (0.64-0.89) 0.001*
BMI Each 1 kg/m2 0.99 0.57 - -
Type II diabetes Yes 2.34 (1.52-3.59) <0.001 1.81 (1.06-3.07) 0.03*
Smoking Yes 1.78 (0.79-4.03) 0.17 - -
Corticosteroid use Yes 1.24 (0.89-1.75) 0.21 - -
Daily sun exposure >15 min/day Reference - Reference -
None 0.85 (0.53-1.36) 0.49 - -
Hyperthyroidism Yes 1.06 (0.60-1.87) 0.84 - -
IBD Yes 1.68 (1.05-2.69) 0.03 1.84 (1.13-2.99) 0.015*
Rheumatoid arthritis Yes 1.13 (0.55-2.29) 0.75 - -
Discordance between femoral neck and spine None Reference - Reference -
Minor 1.80 (1.29-2.51) 0.001 1.45 (1.00-2.10) 0.05*
Major
Parental hip fracture history Yes 1.08 (0.48-2.45) 0.85 - -
Personal fracture history Yes 9.01 (4.85-16.72) <0.001 7.75 (3.87-15.49) <0.001*
Immobility None Reference - Reference -
< 90 days 1.18 (0.78 – 1.77) 0.43 1.06 (0.68-1.66) 0.79
> 90 days 2.70 (1.61-4.51) 0.001 2.19 (1.24-3.86) 0.007*
*CRFs with significant effect on fracture risk.
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tion of fragility fractures.
Thus the FRAX® models need to be calibrated to those
countries where the epidemiology of fracture and death is
known. As a result, in order to analyze the association be-
tween clinical and environmental risk factors (those men-
tioned in FRAX®) and the occurrence of osteoporotic
fracture in the Iranian population, a clinical cohort was
designed to promote the study of different risk factors of
presenting osteoporotic fractures. The current study is the
first such study in the Iranian population.
In corroboration with previous studies, our findings
demonstrated that fracture risk increased with increasing
age and decreasing T-score. Hui et al. reported that the
annual incidence of hip fracture increased by approxi-
mately 30-fold between the ages of 50 and 90 years [33].
Similarly, Kanis et al. showed that the 10-year hip frac-
ture probability increases from 2% in women aged 50 to
12% in women aged 80 years for the same T-score [34].In the present study, in consistency with the aforemen-
tioned findings, each year increase in age after the age of
65 years was associated with 2.62% higher risk in the
whole subcohort population.
Several prospective studies have indicated that the risk
of fracture about doubles for each SD reduction in
BMD, which is much higher than that reported in the
present study [35]. This could be due to the fact that the
majority of those studies were conducted on postmeno-
pausal women, whereas women with a broader age range
were included in our study.
Similarly, prior osteoporotic fracture is known as a
strong predictor of subsequent fracture. While Pluskie-
wicz et al. showed that the presence of prior fracture in-
creased by 1.76 -fold for any osteoporotic fracture, the
multivariable analysis in our study reported a 7.75-fold
higher risk in this regard [36].
Our study revealed that immobility for more than
90 days is associated with a higher risk of major
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immobility for more than 90 days doubles the risk of hip
fracture [37].
Diabetes is another important risk factor for osteopor-
otic fracture. In corroboration with previous studies, our
results showed that diabetes increases the risk of osteo-
porotic fracture by 1.8 [38].
Similar to previous studies, our results reported that
glucocorticoid use is associated with a higher risk of frac-
ture, the association however was not significant [39]. The
reasons for this discrepancy are not fully understood. It
might be related to differences in the study populations,
especially with regard to age and the type of incident frac-
tures or the low power of the study regarding glucocortic-
oid use.
Unlike previous studies, BMI in our study did not have
a marked effect on fracture probability [40]. This could
be due to the fact that BMI could be influenced by
height loss associated with vertebral fractures and de-
formities. Davidson et al. similarly reported that the risk
conferred through BMI could be under- estimated in in-
dividuals with significant height loss [41].
In several studies, falls were reported to be the most
important clinical risk factors for fractures [42,43]. In
the present study, however, history of falls was not iden-
tified as a strong factor, mainly because not many partic-
ipants reported such incidents.
This retrospective cohort revealed that several CRFs
included in FRAX were not significantly associated with
the risk of fracture in our population. Specifically speak-
ing, osteoporosis, diabetes, IBD, immobility for more
than 90 days and personal history of fracture were the
only significant and independent predictors of osteopor-
otic fracture. This may be mainly interpreted as the lack
of predictive value of these CRFs in the target popula-
tion, which is the main difference between our cohort
and those used to develop the FRAX® tool. Lack of stat-
istical power particularly regarding history of smoking,
alcohol use, and other infrequent or under-reported
CRFs might also explain the difference.
Apart from the risk factors taken into account in the
FRAX® score calculation, discordance between spine and
femoral neck BMD was a significant predictor of osteopor-
otic fracture. It can be proposed that adding new parame-
ters to FRAX® may help improve fracture prediction value
of the FRAX tool. Further studies are needed to develop a
more predictive model in our population.
Limitations
Since the cohort is constituted of subjects requiring a
DXA scan (according to their physician), it is likely that
the recruited population will be at a baseline risk greater
than that of the general population. Our results may
therefore be extrapolated to a population in which thephysician is evaluating the risk of low bone mass or frac-
ture (case finding) which is to some extent similar to the
population recommended for investigation by the WHO.
There may be a bias in the collection of the informa-
tion on incidental fractures, which is collected based on
the patient self-report as we did not include radiological
assessment since the patients included were from the
general community and were not seeking medical atten-
tion for bone-related conditions. Moreover, the majority
of vertebral fractures are not clinically diagnosed [44].
Moreover, recall is subject to errors. Additionally smok-
ing and alcohol abuse are underreported as the validity
of self-reported alcohol intake is notoriously unreliable
[45]. The other possible limitation inherent to data col-
lection by telephone was minimized with trained inter-
viewer. However, the reported associations may actually
be stronger than reported here.
Our study had also several strengths. Unlike many pre-
vious studies that were conducted on postmenopausal
women, we enrolled a large group of patients of both
genders and the age range was fairly broad. Also the
large number of studied risk factors allowed obtaining
reliable fracture risk assessment.
In view of the fact that hip fractures represent the mi-
nority of osteoporotic fractures [29] focus on hip frac-
tures alone could be misleading for high-risk younger
individuals whose 10-year risk relates more to spine and
wrist fractures. This is the reason for which not only in
FRAX® but also in our study the patient’s 10-year likeli-
hood of any one of four major osteoporotic fractures are
calculated.
Conclusions
In conclusion, only a limited number of CRFs were found
to be associated with the higher risk of major osteoporotic
fracture. In this population, the majority of risk factors
mentioned in the FRAX® tool along with others such as
discordance between lumbar spine and femoral neck were
associated with increased risk of both hip and major
osteoporotic fractures. These considerations indicate that
assessment can be improved by the integration of other
CRFs into the model. Further studies are needed to deter-
mine a model to improve the sensitivity and specificity
of clinical scores to identify those at high risk of
fracture.
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